Phase I clinical trial using selective cyclooxygenase-2 (Cox-2) inhibitor celecoxib with concurrent thoracic irradiation in patients with poor prognosis non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Liao, Z
Komaki, R
Milas, L
Chen, Y
Chang, JY
Jeter, M
Guerrero, T
Craig, SW
Blumenschien, G
Smith, CM
Cox, JD
机构：
[1] Univ Houston, MD Anderson Canc Ctr, Houston, TX USA
[2] Canc Hosp, Tongji Sch Med, Wuhan, Hu Bei, Peoples R China
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2004年 / 60卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
37
引用
收藏
页码：S151 / S151
页数：1
相关论文
共 50 条
  • [41] Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial
    Nugent, FW
    Mertens, WC
    Graziano, S
    Levitan, N
    Collea, R
    Gajra, A
    Marshall, J
    McCann, J
    LUNG CANCER, 2005, 48 (02) : 267 - 273
  • [42] TG01, a new potent COX-2 inhibitor in combination with erlotinib in metastatic or recurrent non-small cell lung cancer (NSCLC) patients: A phase 1 study
    Reckamp, K. L.
    Patel, R.
    Chen, L.
    Gitlitz, B. J.
    Davies, A. M.
    Jezior, D.
    Zaknoen, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
    Monnet, I
    Brienza, S
    Hugret, F
    Voisin, S
    Gastiaburu, J
    Saltiel, JC
    Soulié, P
    Armand, JP
    Cvitkovic, E
    de Cremoux, H
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) : 1124 - 1127
  • [44] Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC).
    Csiki, I
    Williams, MK
    Shyr, Y
    Sandler, A
    Carbone, DP
    Campbell, N
    Morrow, J
    Johnson, DH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 841S - 841S
  • [45] Phase II trial of carboplatin plus docetaxel combined with a selective cyclooxygenase-2 inhibitor (meloxicam) in first-line treatment of patients with advanced unresectable non-small cell lung cancer: anti-tumor effect and cyclooxygenase-2 expression
    Sekine, Satoko
    Oshima, Kengo
    Ishida, Takashi
    Oizumi, Satoshi
    Yokouchi, Hiroshi
    Yamazaki, Koichi
    Sukoh, Noriaki
    Ogura, Shigeaki
    Munakata, Mitsuru
    Isobe, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S455 - S455
  • [46] Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study
    Likun Chen
    Youjian He
    He Huang
    Hai Liao
    Weidong Wei
    Medical Oncology, 2008, 25 : 161 - 171
  • [47] Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study
    Chen, Likun
    He, Youjian
    Huang, He
    Liao, Hai
    Wei, Weidong
    MEDICAL ONCOLOGY, 2008, 25 (02) : 161 - 171
  • [48] Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer
    Kim, HS
    Youm, HR
    Lee, JS
    Min, KW
    Chung, JH
    Park, CS
    LUNG CANCER, 2003, 42 (02) : 163 - 170
  • [49] Cyclooxygenase-2 Expression in Non-Small Cell Lung Cancer Correlates With Hypertrophic Osteoarthropathy
    Rotas, Ioannis
    Cito, Giovanni
    Letovanec, Igor
    Christodoulou, Michel
    Perentes, Jean Y.
    ANNALS OF THORACIC SURGERY, 2016, 101 (02): : E51 - E53
  • [50] EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features
    Feng Li
    Yongmei Liu
    Huijiao Chen
    Dianying Liao
    Yali Shen
    Feng Xu
    Jin Wang
    Journal of Experimental & Clinical Cancer Research, 30
12345